Skip to main content

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.

Continue reading

Metastatic Castration-Sensitive Prostate Cancer: Real-World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares more regarding the complexities of treatment decisions in prostate cancer, barriers to care, and the research that he and his team are conducting to optimize treatment utilization based on disease characteristics.  

Continue reading